Multivessel Coronary Artery Disease

Slides:



Advertisements
Similar presentations
MAIN-COMPARE Study – Disclosure Information
Advertisements

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Single Center Experience with Drug Eluting Stents for Infrapopliteal Occlusive Disease in Patients with Critical Limb Ischemia: Mid-term follow up Robert.
 An angiographic tool grading the complexity of coronary artery disease  A semiquantitative visual score that will help us to be aware of the anatomical.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
Cardiology Symposium James T. DeVries, MD Assistant Professor of Medicine Dartmouth Medical School Dartmouth-Hitchcock Medical Center.
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
New ESC/EACTS guidelines on myocardial revascularisation Indications for coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
PCI vs. CABG: Review of the evidence and suggestions Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
DR. JAMSHID MOHAJERI MOGHADAM Interventional Cardiologist PCI &CABG.
J Am Coll Cardiol 2008;51:538–45 Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization Pawel E. Buszman,
CABG IN DIABETICS DR. SEYED SAEED FARZAM. Introduction Patients with diabetes mellitus Increased incidence of CAD More extensive disease at angiography.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Revascularization Strategy: Syntax Score and Beyond
S Ten Tse and Sensibility!
From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
Acute and Mid-Term Outcomes of Coronary Stent Implantation for the Treatment of Unprotected Left Main Coronary Artery Disease Dr mahmoud ebrahimi Dr hosein.
CTO Perspectives: When not to Start, and When to Stop and Try Again
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Single Stage CABG and Peripheral Arterial Bypass for Combined Coronary and Peripheral Arterial Disease Divya Arora, Ashok Chahal and Shamsher Singh Lohchab.
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
Giuseppe Biondi Zoccai, MD
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p = 0.32 for noninferiority)
Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD 
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
To bypass or stent? The changing rules of an advancing game
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Multivessel Coronary Artery Disease “IS THE NAIL IN THE COFFIN?” Forrest Glover, M.D. Interventional Cardiologist Jack Steven’s Heart Institute April 25, 2015

What is our goal of therapy? Prevent complications of CAD in effort to prolong life Decrease cardiac morbidity Alleviate symptoms

What are the indications for revascularization? Activity limiting symptoms despite maximal medical therapy Not tolerating medication well or need to increase activity level Anatomy favors survival benefit (significant LMCA disease or multivessel CAD with decreased LVEF)

Will the debate go on forever? Balloon angioplasty vs CABG BARI RITA GABI EAST CABRI

Will the debate go on forever? Bare metal stent vs CABG ERACI - II ARTS SOS Drug eluting stents vs CABG ARTS - II ERACI – III SYNTAX

SYNTAX Trial CABG vs PCI in 3 vessel or LMCA disease 60% patients were 3V CAD 40% LMCA disease Paclitaxel was the DES used

SYNTAX Trial How the score was calculated Amount of segments involved If a CTO was present and if so what type Bifurcation vs trifurcation lesions Ostial lesions Tortuosity Long segment disease Small vessel disease

SYNTAX Trial Composite primary endpoint was higher in PCI vs CABG (17.8% vs 12.4%) Death/MI/Repeat revascularization This was driven by revascularization (13.5% vs 5.9%) Death/Stroke/MI were comparable At 3 and 5 year follow up, primary endpoint remained higher in PCI group (driven by revascularization)

SYNTAX Trial Outcomes were then broken down by disease complexity SS < 23 - no difference in composite endpoint SS 23-32 - endpoint was higher with PCI (37.9% vs 22.6%) SS > 33 - endpoint was higher with PCI (41.9% vs 24.1%)

SYNTAX Trial Criticisms No clinical variables Use of paclitaxel (increased rate of angiographic and clinical restenosis than later generations) Bypass patients were often not on “maximal” medical therapy

SYNTAX II Additional scoring factors Anatomical syntax score Age Creatinine clearance LVEF Presence of unprotected LMCA disease PAD Female sex COPD

PCI preferred 2 vessel CAD especially if LAD is not involved Older patients with significant comorbidities Patients who refuse surgery Patients with low complexity disease that do not have diabetes

PCI or CABG If patients are equally suited Decision should be made by joint team Patients willingness to undergo repeat procedures should be assessed Patients should be aware of slightly higher stroke risk with CABG vs PCI Should not be attempted by low volume operators Assess ability to take DAPT for a long period of time

Case 1 52 year old Woman Diabetic Poor exercise tolerance on stress echo Anterior ischemia

Case 1

Case 2 88 year old woman Severe COPD on home oxygen Unable to walk Renal insufficiency

Case 2

Case 2

Case 2

Case 2

Case 2

Case 2

The Future?